Evidence map›Paper›PMID 31163046›Full record

ArticlePloS one2019

Declining seroprevalence of hepatitis A in Vojvodina, Serbia.

Snežana Medić, Cleo Anastassopoulou, Vesna Milošević, Nataša Dragnić, Smiljana Rajčević, Mioljub Ristić, Vladimir Petrović

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Snežana MedićCenter for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia.ORCID 0000-0002-5778-9861
Cleo AnastassopoulouDivision of Genetics, Cell and Developmental Biology, Department of Biology, University of Patras, Patras, Greece.ORCID 0000-0001-7666-9198
Vesna MiloševićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Nataša DragnićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Smiljana RajčevićCenter for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia.
Mioljub RistićCenter for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia.ORCID 0000-0002-6923-189X
Vladimir PetrovićCenter for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the current hepatitis A virus (HAV) endemicity in the Autonomous Province of Vojvodina, Serbia, we examined the seroprevalence and susceptibility profiles of the general population. A serum bank of 3466 residual samples, collected in 2015-16 as per the specifications of the European Sero-Epidemiology Network 2 project (ESEN2), was tested for anti-HAV antibodies with an enzyme immunoassay. Relationships between anti-HAV positivity and demographic features of respondents were examined by univariable and multivariable analyses. Present-day HAV seroprevalence was compared with that obtained in 1978-79. Surveillance data for hepatitis A recorded between 2008 and 2017 were also analyzed. Age was the only demographic variable found to be independently associated with a HAV seropositive status. Seropositivity (17% overall vs. 79% in 1978-79) increased with age to a maximum of 90% in the elderly ≥60 years. Only 5% of subjects <30 years were seropositive, unlike the 44% of seropositives ≥30 years. The estimated age at midpoint of population immunity (AMPI) increased markedly from 14 years in the late 70s to 55 years in 2015-16. Meanwhile, disease incidence decreased noticeably in recent years (from 11 in 2008 to 2 per 100,000 population in 2017). In the ongoing pre-vaccine era, natural infection provides immunity for merely a third (31%) and two thirds (57%) of people in their 40s and 50s, respectively. Hence, the majority of people ≤40 years (94%) and middle-aged adults 40-49 years (69%) are susceptible to HAV. Older susceptible individuals, particularly those ≥50 years (24%), are prone to severe symptoms. Taken together, these changes reflect the epidemiological transition of Vojvodina and Serbia from high to very low HAV endemicity, thereby supporting the current national policy of immunization of only high-risk groups.

Indexed as

AdolescentAdultAgedChildChild, PreschoolDisease OutbreaksDisease SusceptibilityFemaleHepatitis AHumansIncidenceInfantMaleMiddle AgedSerbiaSeroepidemiologic Studies

Identifiers

PMID31163046
PMCPMC6548380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.